You searched for: dextech
Strengthened DexTech continues to advance towards clinical trials in multiple myeloma
Despite the general price volatility, development work continues unabated in the many biotech companies on the stock exchange. One such example is DexTech, which recently...
DexTech takes a new approach to myeloma treatment
Uppsala-based DexTech is in full swing with preparations for the proof-of-concept study that will evaluate the drug candidate OsteoDex for the treatment of multiple...
New DexTech chairman wants to turn up the volume
With positive phase II data in castration-resistant prostate cancer and upcoming studies in multiple myeloma, DexTech is now taking further steps to...
DexTech's stock pressured despite expanded pipeline
The stock market turbulence of recent months has also left its mark on the biotechnology sector, and one of the many companies affected is...
DexTech Medical's CEO on the company's platform technology
Report-related DexTech Medical develops drug candidates in oncology based on the CDC platform GuaDex, where various substances are combined with the carbohydrate molecule...
DexTech takes the next step with OsteoDex
Following solid Phase II data for OsteoDex in metastatic castration-resistant prostate cancer, Uppsala-based DexTech is advancing its positions. The company is now conducting a...
DexTech's CEO on the company's next development initiative
Uppsala-based DexTech's lead candidate OsteoDex is in advanced clinical development. With strong phase IIb data in metastatic castration-resistant prostate cancer, the company is seeking...
CEO interview DexTech: »OsteoDex is effective even in patients who do not respond to existing treatments«
DexTech Medical is now on track to close its fully underwritten rights issue on June 26. BioStock...
BioStock lists: Stock rockets of the year 2018
Is the general decline in the Swedish stock market in 2018 a sign of a slowing global business cycle, or just...
M&A boom & promising study results in DexTech's favor
Last fall, DexTech Medical hired the global consulting firm EY to intensify the search for a suitable licensee of the company's...
CEO interview: Continued promise in DexTech's prostate cancer study
These days, DexTech Medical was able to report promising results from its phase IIb study with OsteoDex, one of the company's three drug candidates...
DexTech Medical intensifies out-licensing efforts
DexTech Medical has intensified its efforts to identify a suitable partner to license its drug candidate OsteoDex to. OsteDex...